Le Lézard
Classified in: Health
Subject: SVY

Diagnomics Introduces ACMG 59 Reports for Personalized Genetic Testing


SAN DIEGO, Jan. 17, 2019 /PRNewswire/ -- Diagnomics, a leading genetic testing company, has developed a new ACMG 59 report that is available to healthcare providers and their patients to complement Diagnomics' portfolio of Personalized Genomics. Diagnomics has partnered with Fabric Genomics to use Fabric Enterprise, its clinical decision-support platform, to generate clinical insights for the report. Fabric Genomics is the leading provider of genomic interpretation and clinical decision-support software. Their end-to-end software platform provides accurate interpretation for hereditary disease and oncology and allows management and scaling up of genetic workflows from initial testing to final reports. This joint initiative between the two companies is another achievement in making preventive care and personalized medicine widely available across multiple platforms that support genomic solutions.

"At Fabric Genomics, we are passionate about enabling clinical genomic testing at scale," Martin Reese, Ph.D., CEO of Fabric Genomics, commented. "We are excited to announce our partnership with Diagnomics with the first ACMG 59 report, which provides clinical insights across a number of actionable genes and related conditions."

The report offers insights on pathogenic and likely pathogenic variants found within the set of 59 core health genes as recommended by the American College of Medical Genetics and Genomics (ACMG). The analysis is generated from Illumina's Global Screening Array-based assay and other clinical genomic data. Detected variants are evaluated using genotype quality, minor allele frequency and curated clinical databases for pathogenicity. The genes included in this report adhere to ACMG's secondary findings recommendations, most recently updated in November 2016.

Although these recommendations were previously reserved for special cases of high-risk patients, Diagnomics has taken a clinically innovative approach in making the ACMG 59 accessible to all patients. The availability and transparency of information between physicians and patients will play a critical role in supporting clinical decision-making, which will have a significant impact on saving lives, leveraging resources and lowering healthcare costs.

"We continue to invest in personalized genomics analysis capability and are delighted by our collaboration with Fabric Genomics," Byung-In Lee, Ph.D., CEO of Diagnomics, announced. "We have applied innovative strategies to make an expansive test panel both accessible and affordable for clinical use."

Diagnomics' mission to bridge preventive medicine and genetic testing with actionability has engendered the advancement of clinical resources for healthcare providers in empowering their patients to be proactive and make informed decisions concerning their care. The ACMG 59 report serves to highlight the company's commitment to accessibility and applicability of personalized genomics to the individual and the healthcare community.

About Diagnomics Inc.

Diagnomics Inc. is a trusted provider of innovative genetic testing platforms for both organizations and individual consumers. Diagnomics strives to deliver confidence and reliability by offering comprehensive genomic solutions for the development of personalized healthcare and precision medicine in the global genomics market. Diagnomics is a CLIA-certified, CAP-accredited laboratory providing genetic testing platform services and highly secure HIPAA-compliant cloud-based analysis solutions. To learn more, visit www.diagnomics.com.  

SOURCE Diagnomics Inc.


These press releases may also interest you

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....

at 17:58
More than 200 workers at American Medical Response (AMR) in Springfield and Greenfield have voted overwhelmingly to join Teamsters Local 404....

at 17:54
The American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, is celebrating National Doctors Day by highlighting three top kidney medical experts and authors known for their...

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...

at 17:15
Paladin Labs Inc., a subsidiary of Endo International plc , today announced Health Canada's approval of WAKIX® (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged 6 years...

at 17:05
Sirona Biochem Corp. ("Sirona") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in...



News published on and distributed by: